Orchid Pharma Limited Share Price

Equities

ORCHPHARMA

INE191A01027

Pharmaceuticals

Delayed NSE India S.E. 01:38:19 03/06/2024 pm IST 5-day change 1st Jan Change
997.6 INR -0.51% Intraday chart for Orchid Pharma Limited -2.60% +40.06%
Sales 2024 819.37Cr 9.86Cr Sales 2025 * 1.03TCr 12Cr Capitalization 5.09TCr 61Cr
Net income 2024 92Cr 1.11Cr Net income 2025 * 148.6Cr 1.79Cr EV / Sales 2024 6.31 x
Net cash position 2024 132.09Cr 1.59Cr Net cash position 2025 * 164.8Cr 1.98Cr EV / Sales 2025 * 4.78 x
P/E ratio 2024
72.1 x
P/E ratio 2025 *
34 x
Employees 838
Yield 2024 *
-
Yield 2025 *
-
Free-Float 26.03%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Orchid Pharma Limited, Q4 2024 Earnings Call, May 24, 2024
Orchid Pharma Limited Appoints Shubha Singh as Additional Director CI
Orchid Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Orchid Pharma Limited Receives Order from Office of Assistant Commissioner Valluvarkottam Central-III Chennai Central CI
Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director CI
Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention CI
Transcript : Orchid Pharma Limited, Q3 2024 Earnings Call, Feb 09, 2024
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep' CI
Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer CI
Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent) CI
Orchid Pharma Ties Up with GARDP to Manufacture Antibiotic for Certain Gram-Negative Infections MT
Orchid Pharma Limited Enters into Manufacturing Sub License Agreement with Global Antibiotic Research & Development Partnership CI
More news
1 day-0.47%
1 week-2.60%
Current month-0.47%
1 month-4.42%
3 months-16.22%
6 months+72.33%
Current year+40.06%
More quotes
1 week
982.00
Extreme 982
1 041.95
1 month
913.25
Extreme 913.25
1 122.95
Current year
702.75
Extreme 702.75
1 359.95
1 year
408.00
Extreme 408
1 359.95
3 years
265.00
Extreme 265
1 440.00
5 years
17.50
Extreme 17.5
2 654.25
10 years
17.50
Extreme 17.5
2 654.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 31/20/31
Director of Finance/CFO - 29/20/29
Compliance Officer - 16/12
Members of the board TitleAgeSince
Chairman 74 31/20/31
Director/Board Member 42 31/20/31
Chief Executive Officer 56 31/20/31
More insiders
Date Price Change Volume
03/24/03 997.6 -0.51% 36 718
31/24/31 1,003 -0.33% 300,794
30/24/30 1,006 -2.17% 324,158
29/24/29 1,028 -0.11% 44,550
28/24/28 1,030 +0.49% 74,918

Delayed Quote NSE India S.E., June 03, 2024 at 01:38 pm IST

More quotes
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,003 INR
Average target price
1,252 INR
Spread / Average Target
+24.90%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ORCHPHARMA Stock